Quick Answer
Arcadia Biosciences, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $4.86 million for the year ending 2025.
- Arcadia Biosciences, Inc. showed a decrease of -3.7% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Arcadia Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $214.0 thousand | Q2 2018: $436.0 thousand | Q3 2018: $370.0 thousand | Q1 2019: $158.0 thousand | Q2 2019: $203.0 thousand | Q3 2019: $392.0 thousand | Q1 2020: $309.0 thousand | Q2 2020: $281.0 thousand | Q3 2020: $314.0 thousand | Q1 2021: $828.0 thousand | Q2 2021: $1.41 million | Q3 2021: $2.38 million | Q1 2022: $3.22 million | Q2 2022: $3.86 million | Q3 2022: $1.57 million | Q1 2023: $1.23 million | Q2 2023: $1.30 million | Q3 2023: $1.30 million | Q1 2024: $987.0 thousand | Q2 2024: $1.31 million | Q3 2024: $1.54 million | Q1 2025: $1.20 million | Q2 2025: $1.46 million | Q3 2025: $1.30 million.
- Over the full 9 years of available data (2017 to 2025), Arcadia Biosciences, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 20.7%.
- Historical annual values: Fiscal year 2025: $4.86 million | Fiscal year 2024: $5.05 million | Fiscal year 2023: $4.45 million | Fiscal year 2022: $7.42 million | Fiscal year 2021: $6.78 million | Fiscal year 2020: $8.03 million | Fiscal year 2019: $1.17 million | Fiscal year 2018: $1.46 million | Fiscal year 2017: $4.03 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: